Re: Zhang et al.: The biosimilar paradox: how anti-VEGF biosimilars will increase patient and overall healthcare costs (Ophthalmology. 2023;130:966-973)
-
Published:2023-11
Issue:11
Volume:130
Page:e40-e41
-
ISSN:0161-6420
-
Container-title:Ophthalmology
-
language:en
-
Short-container-title:Ophthalmology
Author:
Sharma AshishORCID,
Kumar Nilesh,
Parachuri Nikulaa,
Bandello Francesco
Reference4 articles.
1. The biosimilar paradox: how anti-VEGF biosimilars will increase patient and overall healthcare costs;Zhang;Ophthalmology,2023
2. On label bevacizumab for retina: where it stands;Sharma;Eye (Lond),2022
3. Biosimilars for retinal diseases: United States-Europe awareness survey (Bio-USER - survey);Sharma;Expert Opin Biol Ther,2023
4. Approved biosimilar ranibizumab-a global update;Sharma;Eye (Lond),2023